Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-07-23

Clinical Trial Update: Gentamicin for RDEB [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of gentamicin for Recessive Dystrophic Epidermolysis Bullosa has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gentamicin (gentamicin)

Snippet

Sponsor: University of Southern California | Conditions: Recessive Dystrophic Epidermolysis Bullosa | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-07-23